[go: up one dir, main page]

ECSP14013254A - Nuevos sulfóxidos de piperidino-dihidrotienopirimidina y su uso para tratar epoc y asma. - Google Patents

Nuevos sulfóxidos de piperidino-dihidrotienopirimidina y su uso para tratar epoc y asma.

Info

Publication number
ECSP14013254A
ECSP14013254A ECSP14013254A ECSP14013254A EC SP14013254 A ECSP14013254 A EC SP14013254A EC SP14013254 A ECSP14013254 A EC SP14013254A EC SP14013254 A ECSP14013254 A EC SP14013254A
Authority
EC
Ecuador
Prior art keywords
asthma
piperidine
sulphoxids
dihydrotienopirimidine
new
Prior art date
Application number
Other languages
English (en)
Inventor
Pascale Pouzet
Peter Nickolaus
Chris H Senanayake
Soojin Kim
Ulrike Werthmann
Rogelio Perez Frutos
Thomas G Tampone
Jason Alan Mulder
Bing-Shiou Yang
Nitinchandra Patel
Xudong Wei
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46924393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP14013254(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ECSP14013254A publication Critical patent/ECSP14013254A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La invención se refiere a nuevos sulfóxidos de piperidino-dihidrotienopirimidina de fórmula I, I,en donde el Anillo A es un anillo aromático de 6 miembros que puede comprender opcionalmente uno o dos átomos de nitrógeno y en donde R es Cl y en donde R puede estar ubicado en la posición para, meta u orto del Anillo A, en donde S* es un átomo de azufre que representa un centro quiral,y todas las sales aceptables para uso farmacéutico, enantiómeros y racematos, hidratos y solvatos de los mismos y el uso de estos compuestos para el tratamiento de enfermedades inflamatorias o alérgicas del tracto respiratorio tales como EPOC o asma.
ECSP14013254 2011-08-24 2014-03-18 Nuevos sulfóxidos de piperidino-dihidrotienopirimidina y su uso para tratar epoc y asma. ECSP14013254A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161526861P 2011-08-24 2011-08-24

Publications (1)

Publication Number Publication Date
ECSP14013254A true ECSP14013254A (es) 2014-04-30

Family

ID=46924393

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP14013254 ECSP14013254A (es) 2011-08-24 2014-03-18 Nuevos sulfóxidos de piperidino-dihidrotienopirimidina y su uso para tratar epoc y asma.

Country Status (27)

Country Link
US (3) US20130059866A1 (es)
EP (1) EP2748156B1 (es)
JP (1) JP5851038B2 (es)
KR (1) KR101959194B1 (es)
CN (1) CN103889970B (es)
AP (1) AP2014007401A0 (es)
AR (2) AR087655A1 (es)
AU (1) AU2012298599B2 (es)
BR (2) BR122022002799B1 (es)
CA (1) CA2846183C (es)
CL (1) CL2014000296A1 (es)
CO (1) CO6900138A2 (es)
DK (1) DK2748156T5 (es)
EA (1) EA024033B1 (es)
EC (1) ECSP14013254A (es)
ES (1) ES2563028T3 (es)
HU (1) HUE028531T2 (es)
IL (1) IL230592A0 (es)
MX (1) MX358651B (es)
PE (1) PE20141532A1 (es)
PH (1) PH12014500395A1 (es)
PL (1) PL2748156T4 (es)
TN (1) TN2014000081A1 (es)
TW (1) TWI597283B (es)
UY (1) UY34285A (es)
WO (1) WO2013026797A1 (es)
ZA (1) ZA201400792B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2610258B1 (de) * 2007-10-19 2014-08-27 Boehringer Ingelheim International Gmbh Substituierte Piperidino-Dihydrothienopyrimidine
RU2500681C2 (ru) 2007-10-19 2013-12-10 Берингер Ингельхайм Интернациональ Гмбх Замещенные гетероциклом пиперазинодигидротиенопиримидины
US8486948B2 (en) 2007-10-19 2013-07-16 Boehringer Ingelheim International Gmbh Piperazinodihydrothienopyrimidine derivatives
US20130059866A1 (en) 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
US9802954B2 (en) 2011-08-24 2017-10-31 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
WO2014124860A1 (en) * 2013-02-14 2014-08-21 Boehringer Ingelheim International Gmbh Specific pde4b-inhibitors for the treatment of diabetes mellitus
EP3684775B1 (en) 2017-09-20 2024-11-20 UNION therapeutics A/S Substituted dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
FI3700529T3 (fi) 2017-10-23 2025-09-18 Boehringer Ingelheim Int Uusi aktiivisten aineiden yhdistelmä etenevien fibrotisoivien interstitiaalisten keuhkosairauksien (pf-ild) hoitoon
PT3724196T (pt) 2017-12-15 2023-01-13 Union Therapeutics As Azetidina di-hidrotienopiridinas substituídas e a sua utilização como inibidores de fosfodiesterase
EP3724194B1 (en) 2017-12-15 2023-12-27 UNION therapeutics A/S Substituted azetidine dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
WO2019115775A1 (en) 2017-12-15 2019-06-20 Leo Pharma A/S Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
WO2020055883A1 (en) * 2018-09-11 2020-03-19 Nikang Therapeutics, Inc. 2,3-DIHYDROBENZO[b]THIOPHENE DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS
CN113950435B (zh) 2019-06-25 2024-03-15 本田技研工业株式会社 车辆、车辆的控制方法及存储介质
IL301285A (en) 2020-09-10 2023-05-01 Precirix N V A portion of an antibody against FAP
TW202342050A (zh) * 2021-12-09 2023-11-01 德商百靈佳殷格翰國際股份有限公司 用於治療進行性纖維化間質性肺病之新穎治療組合
MX2024006270A (es) 2021-12-09 2024-06-11 Boehringer Ingelheim Int Nueva composicion farmaceutica oral y regimen de dosificacion para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas.
WO2023150709A2 (en) * 2022-02-04 2023-08-10 Aclaris Therapeutics, Inc. Methods of synthesizing deuterated substituted pyridinone-pyridinyl compounds
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting
US20250326765A1 (en) * 2022-06-02 2025-10-23 Xizang Haisco Pharmaceutical Co., Ltd. Pde4b inhibitor and use thereof
CN117247394A (zh) * 2022-06-16 2023-12-19 武汉人福创新药物研发中心有限公司 作为pde4b抑制剂的含氮杂环类化合物
TW202408518A (zh) * 2022-06-16 2024-03-01 大陸商武漢人福創新藥物研發中心有限公司 Pde4b抑制劑
EP4570804A1 (en) 2022-08-09 2025-06-18 Xizang Haisco Pharmaceutical Co., Ltd. Pde4b inhibitor and use thereof
WO2024068386A1 (en) 2022-09-28 2024-04-04 Boehringer Ingelheim International Gmbh Use of biomarkers in the treatment of fibrotic conditions with a pde4b-inhibitor
CN119698422A (zh) 2022-09-29 2025-03-25 苏州爱科百发生物医药技术有限公司 氮杂稠环类化合物、其制备方法及其在医药上的应用
IL319947A (en) 2022-10-28 2025-05-01 Boehringer Ingelheim Int Heterocyclic compounds as STING antagonists
IL322980A (en) 2023-02-28 2025-10-01 Innovstone Therapeutics Ltd Dihydrothionopyrimidine derivatives and their uses
CN120897920A (zh) 2023-03-20 2025-11-04 勃林格殷格翰国际有限公司 哌啶基-二氢噻吩并嘧啶亚砜的新型多晶型物
CN121127461A (zh) * 2023-04-03 2025-12-12 上海壹迪生物技术有限公司 二氢噻吩并嘧啶类化合物、其制备方法和应用
CN120752243A (zh) 2023-04-13 2025-10-03 上海壹迪生物技术有限公司 取代的二氢噻吩并嘧啶类化合物、其制备方法和应用
CN116370640A (zh) * 2023-04-26 2023-07-04 中国医学科学院基础医学研究所 Pde4b抑制剂在制备预防和/或治疗肺动脉高压的药物中的应用
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy
CN116925099B (zh) * 2023-07-21 2025-06-03 厦门大学 手性二氢噻吩并嘧啶亚砜的制备方法及其应用与其2、4位取代化合物
WO2025067168A1 (zh) * 2023-09-25 2025-04-03 苏州爱科百发生物医药技术有限公司 氮杂稠环类化合物及其制备方法和用途
TW202543644A (zh) 2023-12-19 2025-11-16 德商百靈佳殷格翰國際股份有限公司 用於製造ＰＤＥ４Ｂ抑制劑１－（｛（５Ｒ）－２－［４－（５－氯嘧啶－２－基）哌啶－１－基］－５－氧代－６，７－二氫噻吩并［３，２－ｄ］嘧啶－４－基｝胺基）環丁基］甲醇之方法的新穎合成步驟
CN120398908A (zh) * 2024-02-01 2025-08-01 艾派克斯生物科技有限公司 Pde4b抑制剂及其药物组合物和用途
WO2025228895A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament
WO2025228899A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Further heterocyclic compounds as sting antagonists and the use thereof as medicament
WO2025228902A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Heterocyclic acids as sting antagonists and the use thereof as medicament
US20250333398A1 (en) 2024-04-30 2025-10-30 Boehringer Ingelheim International Gmbh Monoaryl and hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament
WO2025228889A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Monoarylic heterocyclic compounds as sting antagonists and the use thereof as medicament
WO2025228900A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Arylamide substituted indazoles and the use thereof as medicament

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470336A1 (de) 1962-07-04 1969-03-20 Thomae Gmbh Dr K Neue Dihydrothieno-[3,4-d]-pyrimidine und Verfahren zu ihrer Herstellung
NL122810C (es) 1963-06-17
DE1470356A1 (de) 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
DE1940572A1 (de) 1969-08-08 1971-02-11 Thomae Gmbh Dr K Neue 2-Aminoalkylamino-thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
DE2032687A1 (en) 1970-07-02 1972-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Cardiovascular 2-aminoalkylamino-thienopyrimidines - and 4-morpholino derivatives from 4-diethanolamino-compounds by intramolecular cyclisa
BE754606A (fr) 1969-08-08 1971-02-08 Thomae Gmbh Dr K Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication
US3763156A (en) 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
FR2082496A5 (es) 1970-03-18 1971-12-10 Westinghouse Freins & Signaux
DE2121950A1 (en) 1971-05-04 1972-11-23 Dr. Karl Thomae Gmbh, 7950 Biberach Thieno(3,2-d)pyrimidine derivs - with thrombocyte aggregation inhibiting activity
DE2750288A1 (de) 1977-11-10 1979-05-17 Thomae Gmbh Dr K Neue 9-(omega-heteroarylamino- alkylamino)-erythromycine, ihre salze, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
US4256737A (en) 1979-06-11 1981-03-17 Syntex (U.S.A.) Inc. Long acting depot injectable formulations for LH-RH analogues
US5187168A (en) 1991-10-24 1993-02-16 American Home Products Corporation Substituted quinazolines as angiotensin II antagonists
JPH07330777A (ja) 1994-06-08 1995-12-19 Taisho Pharmaceut Co Ltd チエノ［３，２−ｄ］ピリミジン−４−オン誘導体
JPH09301958A (ja) * 1996-05-09 1997-11-25 Nippon Shoji Kk 新規ピリミジン化合物及び抗ロタウイルス剤
US6339089B2 (en) 1997-08-13 2002-01-15 Fujirebio Inc. Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same
AU2001229501A1 (en) 2000-01-24 2001-07-31 Isis Pharmaceuticals, Inc. Antisense modulation of inducible nitric oxide synthase expression
GB0004153D0 (en) 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
EP1326862B1 (de) 2000-10-12 2004-09-15 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Kristallines monohydrat von tiotropiumbromid, verfahren zu dessen herstellung und dessen verwendung zur herstellung eines arzneimittels
DE10064994A1 (de) 2000-12-23 2002-07-04 Merck Patent Gmbh Sulfamidothienopyrimidine
WO2002088138A1 (en) 2001-04-30 2002-11-07 Bayer Corporation Novel 4-amino-5,6-substituted thiopheno[2,3-d]pyrimidines
AR035700A1 (es) 2001-05-08 2004-06-23 Astrazeneca Ab Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados
IL159238A0 (en) 2001-06-22 2004-06-01 Boehringer Ingelheim Pharma Crystalline anticholinergic, method for its production, and use thereof in the production of a drug
US6587548B2 (en) 2001-07-17 2003-07-01 Hewlett-Packard Development Co., L.P. Method and system of using a single telephone number for multiple services
WO2003055890A1 (en) 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
AU2003202263A1 (en) 2002-01-10 2003-07-30 Bayer Healthcare Ag Roh-kinase inhibitors
SE0203304D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Coumpounds
EA008596B1 (ru) 2003-04-29 2007-06-29 Пфайзер Инк. 5,7-ДИАМИНОПИРАЗОЛО[4,3-d]ПИРИМИДИНЫ, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ ГИПЕРТЕНЗИИ
JP2005003345A (ja) 2003-05-21 2005-01-06 Showa Denko Kk 換気兼熱交換装置および空調システム
CA2540617A1 (en) 2003-10-02 2005-04-21 Martek Biosciences Corporation Production of high levels of dha in microalgae using modified amounts of chloride and potassium
MY141220A (en) 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
WO2005082865A1 (ja) 2004-02-27 2005-09-09 Astellas Pharma Inc. 縮合二環性ピリミジン誘導体
US20060074103A1 (en) * 2004-10-06 2006-04-06 Corte James R Cyclic beta-amino acid derivatives as factor Xa inhibitors
CN101163706A (zh) 2005-04-21 2008-04-16 贝林格尔·英格海姆国际有限公司 用于治疗炎性疾病的二氢噻吩并嘧啶
CA2607331A1 (en) 2005-05-11 2006-11-16 Nycomed Gmbh Combination of the pde4 inhibitor roflumilast and a tetrahydrobiopterin derivative
EP1847543A1 (de) 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
CN101687887B (zh) 2007-04-20 2012-08-29 葛兰素集团有限公司 用作抗菌剂的含氮三环化合物
MX2010003826A (es) 2007-10-18 2010-04-21 Boehringer Ingelheim Int Preparacion de dihidrotieno [3,2-d] pirimidinas e intermedios usados en la misma.
RU2500681C2 (ru) 2007-10-19 2013-12-10 Берингер Ингельхайм Интернациональ Гмбх Замещенные гетероциклом пиперазинодигидротиенопиримидины
AU2008312055A1 (en) 2007-10-19 2009-04-23 Astrazeneca Ab Tetrazole derivatives as modulators of metabotropic glutamate receptors (mGluRs)
WO2009053268A1 (de) 2007-10-19 2009-04-30 Boehringer Ingelheim International Gmbh Neue phenyl-substituierte piperazino-dihydrothienopyrimidine
EP2610258B1 (de) 2007-10-19 2014-08-27 Boehringer Ingelheim International Gmbh Substituierte Piperidino-Dihydrothienopyrimidine
FR2922550B1 (fr) 2007-10-19 2009-11-27 Sanofi Aventis Nouveaux derives de 6-aryl/heteroalkyloxy benzothiazole et benzimidazole, application comme medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de cmet
US8486948B2 (en) 2007-10-19 2013-07-16 Boehringer Ingelheim International Gmbh Piperazinodihydrothienopyrimidine derivatives
TW200934785A (en) 2007-10-19 2009-08-16 Schering Corp Compounds for inhibiting KSP kinesin activity
JP2012519159A (ja) 2009-02-27 2012-08-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｄｅ４阻害剤及びｎｓａｉｄを含有する複合薬
US9161927B2 (en) 2009-02-27 2015-10-20 Boehringer Ingelheim International Gmbh Drug combinations containing PDE4 inhibitors and NSAIDs
US20130059866A1 (en) 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma

Also Published As

Publication number Publication date
MX358651B (es) 2018-08-30
US8609670B2 (en) 2013-12-17
MX2014002025A (es) 2014-03-27
JP5851038B2 (ja) 2016-02-03
TW201323427A (zh) 2013-06-16
EP2748156A1 (en) 2014-07-02
UY34285A (es) 2013-02-28
EP2748156B1 (en) 2015-12-16
KR20140060504A (ko) 2014-05-20
US9150586B2 (en) 2015-10-06
EA201400252A1 (ru) 2014-12-30
BR112014003378B1 (pt) 2022-05-17
AU2012298599A1 (en) 2014-02-13
TN2014000081A1 (en) 2015-07-01
TWI597283B (zh) 2017-09-01
CA2846183A1 (en) 2013-02-28
NZ620199A (en) 2015-10-30
ES2563028T3 (es) 2016-03-10
PH12014500395A1 (en) 2014-04-14
CN103889970A (zh) 2014-06-25
DK2748156T3 (en) 2016-03-07
PL2748156T4 (pl) 2025-10-06
EA024033B1 (ru) 2016-08-31
US20130079359A1 (en) 2013-03-28
US20130059866A1 (en) 2013-03-07
AR125150A2 (es) 2023-06-14
CO6900138A2 (es) 2014-03-20
US20150148322A1 (en) 2015-05-28
PL2748156T3 (pl) 2016-07-29
DK2748156T5 (da) 2025-09-15
PE20141532A1 (es) 2014-10-31
AU2012298599B2 (en) 2016-09-22
HUE028531T2 (en) 2016-12-28
IL230592A0 (en) 2014-03-31
CA2846183C (en) 2020-04-28
KR101959194B1 (ko) 2019-03-19
AR087655A1 (es) 2014-04-09
ZA201400792B (en) 2021-08-25
CL2014000296A1 (es) 2014-08-22
CN103889970B (zh) 2016-04-20
WO2013026797A1 (en) 2013-02-28
BR112014003378A2 (pt) 2017-03-01
JP2014524452A (ja) 2014-09-22
BR122022002799B1 (pt) 2022-08-30
AP2014007401A0 (en) 2014-01-31

Similar Documents

Publication Publication Date Title
AR125150A2 (es) Sulfóxidos de piperidino-dihidrotienopirimidina y su uso para tratar epoc y asma
CR20160327A (es) (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
AR090241A1 (es) INHIBIDORES DE LA b-SECRETASA
GT201200346A (es) Derivados de imidazopiridina, su procedimiento de preparaciòn y su aplicaciòn en terapèutica
AR081628A1 (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
ECSP16071151A (es) Inhibidores de dihidropirrolopiridina de ror-gamma
AR098136A1 (es) Compuestos de heteroarilo como inhibidores de btk y usos de los mismos
ECSP14013282A (es) 1-pirazolil-3-(4-((2-anilinopirimidin-4-il)oxi)naftalen-1-il) ureas como inhibidores de proteínas cinasas activadas por mitógeno p38
CL2020000627A1 (es) Nueva combinación de agentes activos para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas (pf-ild).
ECSP15035343A (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida útiles como inhibidores de quinasa pim
AR094964A1 (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRASTORNOS RELACIONADOS CON LA FOSFOINOSITIDA 3-CINASA d (PI3Kd)
MX375789B (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de hepatitis b.
CU20160078A7 (es) Derivados de n-(3-(6-aminopiridin-4-il)fenil)benzamida como inhibidores de btk
BR112013031268A2 (pt) "polipeptídeos análogos de pramlintida, uso dos mesmos, composição farmacêutica compreendendo os referidos polipeptídeos e método de preparação da referida composição".
DOP2012000257A (es) Derivados del acido 1-amino-2-ciclopropiletilboronico
CO6351780A2 (es) Nuevas benzamidas, su preparaccion y su uso como medicamentos
AR092869A1 (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
CL2012001807A1 (es) Compuestos derivados de naftiridina, inhibidores de syk quinasa; compuestos intermediarios, composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades tales como rinitis alergica, asma, epoc, lupus eritematoso, urticaria/angioedema, entre otros.
AR087311A1 (es) Quinolinas sustituidas y su uso como medicamentos
PE20170303A1 (es) Derivados de la indolizina como inhibidores de las fosfoinositido-3 quinasas
CL2016001543A1 (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas.
CO6280536A2 (es) Derivados de azcarbolinas su preparacion y su utilizacion terapeutica como inhibidores de quinasas
UY35419A (es) Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina
MX2018010894A (es) Nuevos inhibidores de fosfatidilinositol 3-quinasa gamma.
CO6630193A2 (es) Inhibidores de la actividad de la proteína tirosina quinasa seleccionada